Press Release
Burlington, MA – May 19, 2008 –
HyperMed, Inc., the leader in hyperspectral medical imaging, today announces it completed $4 million financing
from GBP Capital (GBP) this month. Proceeds will support ongoing marketing and sales of OxyVu™, its lead product.
Mark Carbeau, President and CEO commented: "We are particularly pleased with GBP's enthusiasm in our technology as evidenced
by their expanded investment and ongoing support. OxyVu is proving to be a real advance in wound care diagnostics that helps
surgeons improve patient outcomes and save limbs. This additional capital will help us broaden our platform to include
additional applications."
OxyVu™ is only FDA-approved medical hyperspectral system to non-invasively and quantitatively assess tissue oxygenation in
patients with diabetes and peripheral arterial disease. By supplying clinicians with a tool to analyze tissue metabolism, OxyVu™
may lead to earlier interventions and faster case resolutions.
"GBP's increasing financial commitment is based on HyperMed's continued progress in developing applications for the OxyVu platform,"
said Doug Lind, HyperMed director and Managing Partner for GBP. "Given the high interest level from clinicians in the diabetic and
peripheral vascular markets, we believe the Company's growth prospects are significant."
About Hyperspectral Technology and HyperMed
Hyperspectral Technology (HT) is a novel medical imaging modality that combines advanced optics with sophisticated mathematical
algorithms to identify subtle changes in composition from reflected light. The technology was initially developed by the Department
of Defense for use in aerial espionage and satellite surveillance.
HyperMed has pioneered the use of HT for medical applications. The Company's OxyVu™ system measures oxy-hemoglobin and deoxy-hemoglobin
to enable clinicians to assess tissue metabolism. The company's initial focus is on complications of diabetes and peripheral arterial disease.
Through a simple thirty-second non-invasive scan, a physician gains valuable insights that aid in planning of advanced treatment interventions and surgery.
For more information about HyperMed and the OxyVu™ system, please visit the company's website at
www.hypermed-inc.com.
About GBP Capital
GBP Capital is a Greenwich, CT-based private equity firm focused on financing innovation in the life sciences. The firm was founded in early 2005 by
David S. Wetherell, founder and former CEO of CMGI and innovator in the technology and internet industries. GBP's mission is to improve the human condition
by investing its partners' capital in the most promising early- to mid-stage life science companies. For further information about GBP please visit the
company's website at www.gbpcap.com.
Press Contacts:
HyperMed, Inc.
Harriet Bridges
Marketing Manager
781-229-5900 x6019
hbridges@hypermed-inc.com
GBP Capital
Douglas D. Lind, M.D.
Managing Partner
203-769-2348
dlind@gbpcap.com
www.gbpcap.com
|
